恩帕格利弗洛辛和达帕格利弗洛辛对心力衰竭的结果
Seonghyeon Bu1,2, Mi-Hyang Jung3, Dongjae Lee4
1Division of Cardiology, Department of Internal Medicine, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
JAMA network open
|December 4, 2025
概括
达帕格利弗洛辛和empagliflozin在治疗心力衰竭 (HF) 中表现出类似的有效性. 这项比较研究发现,这两种-葡萄糖共传递体-2 抑制剂之间的心血管死亡或HF住院率没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- -葡萄糖携带载体-2 抑制剂 (SGLT2i) 是已确立的心力衰竭 (HF) 治疗方法.
- 针对特定的SGLT2i,如达帕格利弗洛辛和恩帕格利弗洛辛,对HF管理的有效性数据的比较仍然有限.
研究的目的:
- 在被诊断为心力衰竭的患者中,比较达帕格利弗洛辛与恩帕格利弗洛辛的临床结果.
- 基于左心室喷射率 (LVEF) 的不同心力衰竭表型评估这些SGLT2抑制剂的疗效.
主要方法:
- 一项回顾性队列研究,涉及来自8个医疗中心的4930名HF患者.
- 患者接受了达帕格利弗洛辛或empagliflozin的治疗.
- 使用一对一的倾向性得分匹配来平衡基线特征,然后根据LVEF进行分层 (≤40%,41-49%,≥50%).
主要成果:
- 在达帕格利弗洛辛和恩帕格利弗洛辛组之间的初级综合结果 (心血管死亡或HF住院) 中没有显著差异 (AHR,0.99;95% CI,0.83-1.19).
- 通过LVEF进行的子组分析也显示,这两种SGLT2抑制剂之间的结果没有显著差异.
- 二级结局,包括全因死亡和心血管住院,在治疗组之间没有统计学上显著的差异.
结论:
- 达帕格利弗洛辛和恩帕格利弗洛辛在心力衰竭患者的治疗中表现出相似的临床有效性.
- 这些发现表明,目前的SGLT2抑制剂可能会为HF患者提供类似的益处,无论射出分数如何.
- 需要进一步的前性研究来证实这些结果并指导临床决策.
相关概念视频
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:23Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658